<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732990</url>
  </required_header>
  <id_info>
    <org_study_id>VEK-H-3-2013-048</org_study_id>
    <nct_id>NCT02732990</nct_id>
  </id_info>
  <brief_title>Peripheral Metabolic Function in Chronic Heart Failure Patients</brief_title>
  <official_title>Peripheral Metabolic Function in Chronic Heart Failure Patients: Key to Lessen the Cardiac Load</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anders Rasmussen Rinnov</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exercise intolerance is a major limiting symptom in patients with CHF. However the poor&#xD;
      correlation between the hemodynamic parameters of left ventricular performance at rest and&#xD;
      exercise performance has led to the concept that peripheral factors such as muscle perfusion&#xD;
      and muscle metabolism play a role as determinants of exercise capacity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pathophysiology behind the breathlessness and fatigue experienced by CHF patients during&#xD;
      exercise remains unclear. Recent evidence suggests that the peripheral skeletal muscle, which&#xD;
      becomes abnormal in heart failure, is the source of afferent signals which disrupt normal&#xD;
      patterns of cardiorespiratory control. When CHF patients exercise, an inappropriately strong&#xD;
      sympathetic response further limits exercise tolerance by evoking larger than normal&#xD;
      increases in peripheral sympathetic activation at a faster rate than in healthy individuals.&#xD;
      A consequence of this exacerbated sympathetic response may be the further sympathetic&#xD;
      restraint of blood flow to the active skeletal muscles resulting in hypoperfusion of the&#xD;
      muscle vascular bed and fatigue. Small muscle mass exercise training increases muscle&#xD;
      oxidative capacity and improves aerobic work capacity in CHF patients. A range of studies is&#xD;
      proposed here that will provide an integrative view of the mechanistic basis behind exercise&#xD;
      intolerance in CHF and relate the intramuscular metabolic status to the autonomic control of&#xD;
      hemodynamics during exercise. An understanding of the mechanistic basis of the improved&#xD;
      exercise tolerance with training, independent of improved resting cardiac function, will&#xD;
      yield important information regarding the integrated control of blood flow and metabolic&#xD;
      demand in CHF and highlight the importance of maintaining the integrity of the peripheral&#xD;
      musculature in CHF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline sympathetic nerve activity after 6 weeks of training</measure>
    <time_frame>6 weeks</time_frame>
    <description>Sympathetic nerve activity, measured in plasma and dialysat with reference to nor-adrenaline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect of exercise training on exercise capacity in regards to oxygen uptake</measure>
    <time_frame>6 weeks</time_frame>
    <description>Exercise capacity in regards to oxygen uptake (VO2peak) will be evaluated before and after the training intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of exercise training on exercise capacity in regards to maximal workload</measure>
    <time_frame>6 weeks</time_frame>
    <description>Exercise capacity in regards to Workload during 2-legged cycling (Wattpeak) will be evaluated before and after the training intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of exercise training on exercise capacity in regards to a 6 min walk test</measure>
    <time_frame>6 weeks</time_frame>
    <description>Exercise capacity in regards to a 6 min walk test (meters) will be evaluated before and after the training intervention</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Exercise training - Whole body exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control subjects will train 2-legged cycling (whole body exercise) for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise training - One-legged exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control subjects will train high intense one-legged exercise for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise training - 2-legged cycling CHF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF patients will train 2-legged cycling (whole body exercise) for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise training - CHF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF Patients will train high intense one-legged exercise for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise training</intervention_name>
    <description>All gruoups will undergo 6 weeks of training intervention either with a small musclemass (one-legged exercise) or whole body exercise (two-legged cycling)</description>
    <arm_group_label>Exercise training - 2-legged cycling CHF</arm_group_label>
    <arm_group_label>Exercise training - CHF</arm_group_label>
    <arm_group_label>Exercise training - One-legged exercise</arm_group_label>
    <arm_group_label>Exercise training - Whole body exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  New York Heart Association (NYHA) Class II - III&#xD;
&#xD;
          -  Ejection fraction &lt;35%&#xD;
&#xD;
          -  Heart failure as a result of previous myocardial infarction&#xD;
&#xD;
          -  Optimal treatment (ACE-inhibitors, beta-blockers)&#xD;
&#xD;
          -  Stable heart failure&#xD;
&#xD;
          -  Patients with and without implantable cardioverter defibrillator (ICD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Peripheral vascular disease with symptoms of atherosclerosis (intermittent&#xD;
             claudication)&#xD;
&#xD;
          -  Aneurysm in a. femoral&#xD;
&#xD;
          -  Moderate to severe heart valve disease&#xD;
&#xD;
          -  Moderate to severe Chronic Obstructive Pulmonary Disease (COPD) with FEV1 &lt;60%&#xD;
&#xD;
          -  Heart Failure Patients with Biventricular pacemaker (BVP)&#xD;
&#xD;
          -  Serious heart rhythm disturbances (arrhythmias such as atrial fibrillation and&#xD;
             frequent premature ventricular contractions)&#xD;
&#xD;
          -  Myocardial infarction within the last month&#xD;
&#xD;
          -  Unstable angina (angina pectoris)&#xD;
&#xD;
          -  Renal failure (creatinine greater than 2.5 mg / dL)&#xD;
&#xD;
          -  Severe systemic disease of the nervous system, pulmonary or other severe organ&#xD;
             involvement&#xD;
&#xD;
          -  BMI&gt; 30&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan P Mortensen, Dr. Med</last_name>
    <role>Study Chair</role>
    <affiliation>IMM - Department of Cardiovascular and Renal Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gregers W Munch, MSc PhD</last_name>
    <phone>+45 35459574</phone>
    <email>gregers.munch@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre of Inflammation and Metabolism (CIM), Centre for Physical Activity Research</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregers W Munch, MSc PhD</last_name>
      <phone>+45 35459574</phone>
      <email>gregers.munch@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>November 6, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <last_update_submitted>April 4, 2016</last_update_submitted>
  <last_update_submitted_qc>April 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Anders Rasmussen Rinnov</investigator_full_name>
    <investigator_title>CIM administrator</investigator_title>
  </responsible_party>
  <keyword>Training</keyword>
  <keyword>One-legged exercise</keyword>
  <keyword>Peripheral blood flow</keyword>
  <keyword>Cardiac function</keyword>
  <keyword>Muscle metaboreflex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

